DOI: 10.21276/sajp.2018.7.6.6

Pages: 249-253

Chronic bronchitis is a relatively common infection among patients suffering from chronic obstructive pulmonary disease (COPD). Usual management includes pulmonary hygiene, bronchodilators, and antimicrobial therapy. This study will be conducted to compare the efficacy of Levofloxacin and Co-Amoxiclav in the management of chronic bronchitis among ambulatory patients with COPD in King Hussein Medical Centre (KHMC) at the Royal Medical Services (RMS) in Jordan/Amman. A prospective observational study will be performed on patients each in Levofloxacin and Co-Amoxilav group, who are receiving treatment for chronic bronchitis. Demographic and clinical data will be taken from the patients’ medical records. The clinical success rates were superior in 89.3% of patients in the Levofloxacin group versus 61.8% of those in the Co-Amoxiclav group. The pulmonary function test (PFT) significantly increased in Levofloxacin study group compared with Co-Amoxiclav group (P value 0.033). A 7-day course of levofloxacin was convenient with once daily dose, and found to be therapeutically superior to Co-Amoxiclav in terms of clinical effectiveness for the treatment of AECB patients.